Literature DB >> 31706554

The influence of adjuvant therapy on survival in patients with indeterminate margins following surgery for non-small cell lung cancer.

Vignesh Raman1, Oliver K Jawitz2, Chi-Fu J Yang3, Soraya L Voigt2, Anthony W Kim4, Betty C Tong2, Thomas A D'Amico2, David H Harpole2.   

Abstract

BACKGROUND: The significance of indeterminate margins following surgery for non-small cell lung cancer (NSCLC) is unknown. We evaluated the influence of adjuvant therapy on survival in patients whose cancer showed indeterminate margins.
METHODS: Patients whose cancer showed indeterminate margins following surgery for NSCLC were identified in the National Cancer Database between 2004 and 2015, and stratified by receipt of adjuvant treatment. The primary outcome was overall survival, which was evaluated with multivariable Cox proportional hazards.
RESULTS: Indeterminate margins occurred in 0.31% of 232,986 patients undergoing surgery for NSCLC and was associated with worse survival compared with margin negative resection (adjusted hazard ratio, 1.53; 95% confidence interval, 1.40-1.67). Anatomic resection was protective against the finding of indeterminate margins in logistic regression. Amongst 553 patients with indeterminate margins, 343 (62%) received no adjuvant therapy, 96 (17%) received adjuvant chemotherapy, 33 (6%) received adjuvant radiation, and 81 (15%) received adjuvant chemoradiation. Any mode of adjuvant therapy was not associated with improved survival compared with no further treatment.
CONCLUSIONS: The finding of indeterminate margins is reported in 0.31% of patients undergoing curative-intent surgery for NSCLC. This was associated with worse overall survival compared with complete resection and not mitigated by adjuvant therapy. The risks and benefits of adjuvant therapy should be carefully considered for patients with indeterminate margins after surgery for NSCLC.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  lung cancer; margins; non–small cell lung cancer; surgery

Mesh:

Year:  2019        PMID: 31706554      PMCID: PMC7399537          DOI: 10.1016/j.jtcvs.2019.09.075

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  17 in total

1.  Prognostic implications of a positive bronchial resection margin.

Authors:  G Massard; C Doddoli; B Gasser; X Ducrocq; R Kessler; C Schumacher; G M Jung; J M Wihlm
Journal:  Eur J Cardiothorac Surg       Date:  2000-05       Impact factor: 4.191

2.  Get it right the first time.

Authors:  Thomas A D'Amico
Journal:  J Thorac Cardiovasc Surg       Date:  2017-04-05       Impact factor: 5.209

3.  Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery.

Authors:  Jacquelyn G Hancock; Joshua E Rosen; Alberto Antonicelli; Amy Moreno; Anthony W Kim; Frank C Detterbeck; Daniel J Boffa
Journal:  Ann Thorac Surg       Date:  2014-12-17       Impact factor: 4.330

4.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Authors:  Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

5.  Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer.

Authors:  H S Hofmann; C Taege; C Lautenschläger; H Neef; R E Silber
Journal:  Eur J Cardiothorac Surg       Date:  2002-04       Impact factor: 4.191

6.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

Authors:  Rodrigo Arriagada; Bengt Bergman; Ariane Dunant; Thierry Le Chevalier; Jean-Pierre Pignon; Johan Vansteenkiste
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

7.  The importance of the lumpectomy surgical margin status in long-term results of breast conservation.

Authors:  M C Smitt; K W Nowels; M J Zdeblick; S Jeffrey; R W Carlson; F E Stockdale; D R Goffinet
Journal:  Cancer       Date:  1995-07-15       Impact factor: 6.860

8.  Unsuspected residual disease at the resection margin after surgery for lung cancer: fate of patients after long-term follow-up.

Authors:  C Lequaglie; B Conti; P P Brega Massone; G Giudice
Journal:  Eur J Cardiothorac Surg       Date:  2003-02       Impact factor: 4.191

9.  Margin and local recurrence after sublobar resection of non-small cell lung cancer.

Authors:  Amgad El-Sherif; Hiran C Fernando; Ricardo Santos; Brian Pettiford; James D Luketich; John M Close; Rodney J Landreneau
Journal:  Ann Surg Oncol       Date:  2007-05-16       Impact factor: 5.344

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  1 in total

1.  A year in general thoracic surgery published in the Journal of Thoracic and Cardiovascular Surgery: 2020.

Authors:  Michael Lanuti; Jules Lin; Thomas Ng; Bryan M Burt
Journal:  J Thorac Cardiovasc Surg       Date:  2021-04-20       Impact factor: 5.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.